Citigroup
CTOR icon

Citigroup’s Citius Oncology CTOR Stock Holding History

Citigroup’s Portfolio CTOR Stock Details CTOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1 Buy
+1
New +$1 ﹤0.01% 5966

Other funds holding CTOR

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
IFP Advisors
IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return
Private Advisor Group
Private Advisor Group Morristown, New Jersey $29.9B AUM 19.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
StoneX Group
StoneX Group New York $2.75B AUM 24.13% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.26% 1-Year Est. Return

Citigroup's CTOR Position: Q3 2026 in Review

Citigroup opened a new position in Citius Oncology (CTOR) in Q3 2026: 1 share worth $1. The stake represents ﹤0.01% of the portfolio and ranks #5966 among its holdings.

7 funds tracked by Wall St. Rank hold CTOR as of Q3 2026.

  • Citigroup held 1 share of Citius Oncology worth $1 as of Q3 2026.
  • Citius Oncology was a new Citigroup position in Q3 2026.
  • Citius Oncology made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #5966 holding.
  • 7 funds tracked by Wall St. Rank held Citius Oncology as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.